Theraclion SA (TCLIF) Price & Analysis

4 Followers

TCLIF Stock Chart & Stats

$0.53

$0.21(66.25%)

At close: Apr 08 4:00 PM EDT

$0.53

$0.21(66.25%)

Day’s Range― - ―

52-Week Range$0.32 - $0.53

Previous CloseN/A

Volume500.00

Average Volume (3M)0.00

Market Cap

$57.87M

Enterprise Value$45.63M

Total Cash (Recent Filing)$5.22M

Total Debt (Recent Filing)$4.95M

Price to Earnings (P/E)―

Beta0.00

Next Earnings

Apr 29, 2027

EPS EstimateN/A

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-0.10

Shares OutstandingN/A

10 Day Avg. Volume0

30 Day Avg. Volume0

Financial Highlights & Ratios

PEG Ratio0.33

Price to Book (P/B)-13.53

Price to Sales (P/S)29.53

P/FCF Ratio-4.89

Enterprise Value/Market Cap0.79

Enterprise Value/Revenue44.96

Enterprise Value/Gross Profit-5.99

Enterprise Value/Ebitda-6.28

Forecast

1Y Price TargetN/A

Price Target UpsideN/A

Rating ConsensusN/A

Number of Analyst Covering0

EPS Forecast (FY)N/A

Revenue Forecast (FY)N/A

Bulls Say, Bears Say

Bulls Say

Non-invasive Therapeutic TechnologyTheraclion’s focus on non-invasive, image-guided treatment addresses procedures where avoiding surgery may be clinically valuable. A specialized technology platform in established thyroid and breast indications can support durable differentiation and continued commercialization as provider adoption develops.

Recurring Revenue OpportunitiesThe business model extends beyond one-time system sales through procedure-linked consumables and service contracts. If installed systems expand, these recurring elements can improve revenue visibility, deepen provider relationships, and create additional monetization from each treatment platform.

Reported EPS ImprovementReported positive EPS growth indicates some year-over-year improvement in per-share earnings metrics, even though the company remains loss-making. Continued improvement could eventually support operating leverage, but the evidence currently represents progress rather than established profitability.

Bears Say

Persistent Unprofitable OperationsPersistent losses across gross, operating, and net levels show that the current revenue base does not support the cost structure. Without a sustained improvement in revenue or margins, profitability remains structurally unresolved and may continue consuming capital over the next several quarters.

Ongoing Cash BurnConsistently negative operating and free cash flow means the business is not yet funding operations internally. The approximately €7.2M 2025 cash outflow indicates continued dependence on external funding, reducing flexibility to invest, absorb setbacks, or scale independently.

Negative Equity And Meaningful DebtRecurring negative equity signals that past losses have eroded the capital base, while debt is substantial relative to annual revenue. This combination raises solvency and financing risk, limits financial flexibility, and can constrain the company’s ability to fund growth without additional capital.

Theraclion SA News

Theraclion gains bullish TP ICAP Midcap coverage on Sonovein’s growth potential

Theraclion SA ( ($FR:ALTHE) ) just unveiled an announcement. Theraclion has received initial equity research coverage from TP...

3d ago

Theraclion deepens losses as it ramps up for Sonovein’s global push and awaits FDA ruling

An update from Theraclion SA ( ($FR:ALTHE) ) is now available. Theraclion reported a first-half 2026 operating loss...

1M ago

Theraclion Updates Share Capital and Voting Rights Structure

Theraclion SA ( ($FR:ALTHE) ) has shared an update. Theraclion has disclosed its latest share capital and voting...

2M ago

Theraclion accelerates Sonovein rollout as China and U.S. strategies take shape

Theraclion SA ( ($FR:ALTHE) ) has shared an update. Theraclion reported that commercial momentum for its Sonovein varicose‑vein...

3M ago

TCLIF FAQ

What was Theraclion SA’s price range in the past 12 months?

Theraclion SA lowest stock price was $0.32 and its highest was $0.53 in the past 12 months.

What is Theraclion SA’s market cap?

Theraclion SA’s market cap is $57.87M.

When is Theraclion SA’s upcoming earnings report date?

Theraclion SA’s upcoming earnings report date is Apr 29, 2027 which is in 180 days.

How were Theraclion SA’s earnings last quarter?

Theraclion SA released its earnings results on Sep 16, 2026. The company reported -$0.056 earnings per share for the quarter.

Is Theraclion SA overvalued?

According to Wall Street analysts Theraclion SA’s price is currently Overvalued. Get more investment ideas with TipRanks Premium

Does Theraclion SA pay dividends?

Theraclion SA does not currently pay dividends.

What is Theraclion SA’s EPS estimate?

Theraclion SA’s EPS estimate for its next earnings report is not yet available.

How many shares outstanding does Theraclion SA have?

Currently, no data Available

What happened to Theraclion SA’s price movement after its last earnings report?

Theraclion SA reported an EPS of -$0.056 in its last earnings report. Following the earnings report the stock price went same 0%.

Which hedge fund is a major shareholder of Theraclion SA?

Currently, no hedge funds are holding shares in TCLIF

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Company Description

Theraclion SA

Theraclion SA, established in 2004 and based in Malakoff, France, specializes in developing innovative echotherapy medical solutions. These treatments harness high-intensity focused ultrasound (HIFU) technology. Their offerings include SONOVEIN, a robotic, non-surgical echotherapy system designed for addressing varicose veins, and ECHOPULSE, a similar robotic, non-invasive solution for treating thyroid nodules and breast fibroadenoma. Furthermore, the company provides EPack, a disposable component used during procedures to protect the patient's skin and enhance image clarity.